Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | NPC1 | O15118 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30300673 | 0.85 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2RXFP1CISD2 | |
| SCHEMBL1703648 | 0.83 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2RXFP1CISD2 | |
| SCHEMBL1704320 | 0.82 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2RXFP1CISD2 | |
| SCHEMBL7532801 | 0.81 | FADS1 (0.59) | RAB9ANPC1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL1703428 | 0.79 | DHODH (0.51) | RAB9ANPC1SMN1; SMN2RXFP1CISD2 | |
| SCHEMBL890809 | 0.78 | MAPT (0.55) | KMT2AALDH1A1MEN1GAAMAPT | |
| SCHEMBL9208778 | 0.78 | NPC1 (0.71) | RAB9ANPC1SMN1; SMN2RXFP1KMT2A | |
| SCHEMBL30726106 | 0.78 | NPC1 (0.71) | RAB9ANPC1SMN1; SMN2RXFP1KMT2A | |
| SCHEMBL2530312 | 0.78 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2RXFP1KMT2A | |
| SCHEMBL2533805 | 0.77 | SMN1; SMN2 (0.62) | RAB9ANPC1SMN1; SMN2RXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2441768-A1 | Thienopyrimidinones for treatment of inflammatory disorders and cancers | Eli Lilly & Co. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
| EP-2097422-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | Eli Lilly & Co. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008064018-A1 | THIENOPYRIMIDINONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ELI LILLY & CO. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | PIK3CA, PIK3CD, PIK3CB | RAB9A 1996/4885NPC1 3005/4885SMN1; SMN2 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.